针对阿尔茨海默病检测和痴呆风险降低的模块化工具箱的验证,部署和现实世界的实施:AD-RIDDLE项目
K Malzbender1, P Barbarino, P Barkman Ferrell
1Miia Kivipelto, MD, PhD, Center for Alzheimer's Research, Karolinska Universitetssjukhuset, Karolinska Vägen 37 A, QA32, 171 64 Solna, Sweden, Email: miia.kivipelto@ki.se, Phone: +46 73 99 409 22.
The journal of prevention of Alzheimer's disease
|February 20, 2024
概括
该AD-RIDDLE项目正在开发一个工具箱,以改善阿尔茨海默病 (AD) 的检测和治疗. 该倡议旨在加速创新,并加强欧洲各地的患者护理.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 卫生系统研究 卫生系统研究
背景情况:
- 阿尔茨海默病 (AD) 在及时检测和治疗干预方面存在重大挑战.
- 现有的障碍阻碍了AD在连续的有效管理,从无症状到症状阶段.
研究的目的:
- 开发,测试和部署一个模块化工具箱平台,用于早期检测和改善阿尔茨海默病的生活方式.
- 通过专注于整个临床途径的卫生系统和卫生工作者实践来改善AD管理.
- 通过提高认识,降低风险,预防,检测,诊断和干预,加速AD创新.
主要方法:
- 在AD-RIDDLE项目涉及24个合作伙伴在六个欧洲国家的跨学科联盟.
- 开发和测试一个模块化工具箱平台及其组件,单独和组合.
- 专注于卫生系统整合和卫生工作者实践,以促进现实世界的实施.
主要成果:
- 预期的工具可以更早,更准确地诊断阿尔茨海默病.
- 验证用于AD检测的新型数字认知和基于血液的生物标志物.
- 改善对个性化的预防干预措施的获取,包括多模式和精准医学方法.
结论:
- 预计AD-RIDDLE工具箱平台将推进阿尔茨海默病的管理.
- 实施将改善患者和家庭的结果,并可能降低医疗保健成本.
- 该项目旨在通过协作,跨部门的方法加速阿尔茨海默病护理方面的创新.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
相关概念视频
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
